William Blair Brokers Decrease Earnings Estimates for VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Stock analysts at William Blair cut their FY2025 earnings estimates for shares of Vertex Pharmaceuticals in a research note issued to investors on Tuesday, November 4th. William Blair analyst M. Minter now expects that the pharmaceutical company will earn $15.95 per share for the year, down from their prior forecast of $15.99. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals’ Q4 2025 earnings at $4.23 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.58 by $0.22. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm’s revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.38 EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

VRTX has been the topic of a number of other reports. Wall Street Zen cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 22nd. Cantor Fitzgerald decreased their price target on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. Raymond James Financial initiated coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating for the company. Leerink Partnrs raised shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $489.45.

Vertex Pharmaceuticals Stock Down 0.2%

Shares of VRTX stock opened at $416.25 on Friday. The business has a 50-day moving average price of $404.18 and a two-hundred day moving average price of $430.46. Vertex Pharmaceuticals has a 12-month low of $362.50 and a 12-month high of $519.88. The firm has a market cap of $106.72 billion, a P/E ratio of 29.75 and a beta of 0.36.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Activest Wealth Management bought a new position in shares of Vertex Pharmaceuticals during the first quarter valued at about $25,000. Chesapeake Asset Management LLC increased its holdings in Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 33 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its position in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 45 shares during the last quarter. Access Investment Management LLC bought a new position in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $27,000. Finally, Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter worth approximately $29,000. Institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.